Relief as South Africa Moves to Produce Breakthrough HIV Injection for Africa

A South African laboratory will soon produce a generic version of a groundbreaking HIV treatment, marking a major step toward medical self-reliance across the continent. Unitaid announced the development, highlighting its potential to expand access to advanced HIV care while reducing dependence on imported drugs.

The treatment, known as lenacapavir and developed by US-based pharmaceutical firm Gilead, is an injectable drug administered only twice a year.

As a result, it offers a practical alternative for patients who struggle with daily medication. Experts say the innovation could significantly improve adherence to HIV prevention and treatment.

“Together with Gilead, we have an agreement with the government of South Africa for this drug to be produced in South Africa as soon as possible,” Unitaid executive director Philippe Duneton said.

Notably, lenacapavir has attracted global attention due to its effectiveness. Studies show it reduces the risk of HIV transmission by 99.9 percent. In contrast to daily pills, the twice-yearly injection provides a more discreet option, especially for women who often face stigma linked to HIV treatment.

Push for Local Pharmaceutical Production

Speaking during a Franco-African economic summit in Nairobi on Tuesday, May 12, 2026, Duneton stressed the need to strengthen Africa’s pharmaceutical manufacturing capacity.

He described the initiative as a very important step and added that investment in regional medicine production is absolutely essential.

Moreover, the COVID-19 pandemic exposed major gaps in global health systems. Many African countries struggled to access vaccines as wealthier nations prioritised their populations.

Consequently, leaders renewed calls for Africa to build its own manufacturing capabilities.

Also Read: Faith vs. Science: Lawyer Danstan Omari Challenges KEMRI Over Prophet Owuor HIV “Healing” Miracle

Manufacturing Process Underway

At the same time, discussions between Unitaid and Gilead have progressed over several years. Duneton confirmed that a “preliminary agreement” already exists. However, both sides will finalise the deal after selecting a suitable South African laboratory to produce the generic drug. A call for tenders is already underway.

“I have every confidence in what is going to happen. It takes months of discussions. We have been talking for years,” he told AFP.

Once the partners identify a manufacturer, production could begin within one to two years. Although the process takes time, it will ensure the drug meets safety and quality standards.

Also Read: Win for Kenya as Ministry Launches Long-Acting HIV Prevention Injection

Strengthening Health Security

Beyond access, the initiative also aims to build resilience in Africa’s health systems. Duneton emphasised the importance of local production, especially during global disruptions.

“When there are tensions, competition or disruptions in supply chains, it’s better to have medicines produced close to home. That holds true everywhere, in Europe as well as in Africa,” he said.

Ultimately, the move could improve access to life-saving HIV treatment while preparing the continent to respond more effectively to future health crises.

Follow our WhatsApp channel for instant news updates

Unitaid Executive Director Philippe Duneton during a past address. PHOTO/ Unitaid X